OxSonics
Generated by Meeveem AI
"Enhancing cancer drug delivery through ultrasound technology for solid tumour treatment."
Oxford
•11 - 50 Employees
•Medical Devices
About OxSonics
OxSonics develops SonoTran®, an ultrasound platform that tackles a critical oncology barrier: getting anti-cancer drugs deep into solid tumours. Around 90% of adult cancers are solid tumours, and poor drug penetration limits treatment effectiveness. SonoTran® uses ultrasound and proprietary particles to create mechanical pumping that enhances drug delivery without reformulation. This clinical-stage platform works with existing and emerging therapies, integrating into current care pathways. For pharmaceutical partners, it improves trial success. For clinicians, it offers an intuitive solution designed by medical professionals. For patients facing challenging cancers, it delivers smarter, more effective treatment.
30
Team Members
2013
Founded
Medical Devices
Sector
On-Site
Work Environment
Our Vision
A world where every cancer patient receives the most effective treatment possible, with drugs reaching every part of their tumour to maximise therapeutic benefit and improve survival outcomes.
Our Mission
At OxSonics, our mission is to develop ground-breaking ultrasound technology that enhances the delivery and effectiveness of anti-cancer drugs for patients with solid tumours.